ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product

Rhea-AI Summary

ViaDerma, Inc. (OTC Pink: VDRM) has announced the brand name Nupelo for its upcoming minoxidil hair regrowth product. The company recently submitted an application for FDA registration, expected to be completed within weeks. Nupelo will utilize ViaDerma’s proprietary dual carrier transdermal delivery technology, aimed at effectively regrowing hair rather than just reducing hair loss. The product is set to launch for purchase online by the end of Q2 2023, with availability on various platforms including nupelo.com. CEO Dr. Chris Otiko highlighted the speed and effectiveness of the development process.

Positive

• Successful application submitted for FDA registration of Nupelo hair regrowth product.
• Quick FDA approval process expected within weeks.
• Nupelo features proprietary dual carrier transdermal delivery technology.
• Product anticipated to launch by the end of Q2 2023.

Negative

• None.

The Company unveils brand name for its planned minoxidil hair regrowth product

LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce that the company has recently submitted their application for their planned minoxidil hair regrowth product for FDA registration status approval. The FDA registration process should be relatively quick, and we expect this process to be completed within a few weeks.

The company has chosen Nupelo as the brand name for its new hair regrowth product. Nupelo will incorporate ViaDerrma’s proprietary, patent-pending dual carrier transdermal delivery technology and use Minoxidil (topical route) in their new hair regrowth product. 

ViaDerma plans to make Nupelo available for purchase via several online platforms including their newly acquired domain, nupelo.com. The product is expected to be ready to go to market and available to purchase online by the end of Q2 2023.

"Everything has really come together very quickly and smoothly. Due to the extreme effectiveness of our proprietary transdermal delivery system, we are able to develop new products like Nupelo in a very short period of time. Many other hair products only work to reduce hair loss, but are ineffective at actually regrowing hair. Nupelo works to solve both," said ViaDerma’s President & CEO, Dr. Chris Otiko.

About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit: https://viaderma.com

Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.

Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter: https://twitter.com/viaderma
Follow ViaDerma on Facebook: https://www.facebook.com/ViaDermaLicensing/

 

FAQ

What is Nupelo in relation to ViaDerma (VDRM)?

Nupelo is the brand name for ViaDerma's new minoxidil hair regrowth product.

When will Nupelo be available for purchase?

Nupelo is expected to be available online by the end of Q2 2023.

What technology does Nupelo utilize?

Nupelo incorporates ViaDerma’s proprietary dual carrier transdermal delivery technology.

What status has ViaDerma (VDRM) applied for regarding Nupelo?

ViaDerma has submitted an application for FDA registration status for Nupelo.

How quickly is the FDA registration process expected for Nupelo?

The FDA registration process is expected to be completed within a few weeks.